the former director of the Centers for Disease Control and Prevention, has been named president of Merck Vaccines, effective Jan. 25. In her new role, Gerberding, 54, will lead the company’s $5 billion global vaccine business, which markets pediatric, adolescent and adult vaccines and provides vaccines in countries worldwide. Gerberding replaces Margie McGlynn, who retired from Merck Nov. 1, 2009, according to a company spokesman. Gerberding will oversee the commercialization of the current portfolio of vaccines, plan for the introduction of vaccines from the company’s pipeline, and quicken the company’s efforts to broaden access to its vaccines in developing countries. Gerberding served as director at the CDC from 2002 until 2009, where she led the HHS agency during more than 40 emergency-response initiatives for health crises, including anthrax bioterrorism, food-borne disease outbreaks and natural disasters. She also advised governments in other countries about public health issues such as SARS, AIDS and obesity.